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The discovery that the somatic activating missense muta-
tion T1796A, leading to the substitution of glutamate to
valine (V600E—previously known as V599E1) in the kinase
domain of BRAF, was found in 66% of human melanomas
(Davies et al, 2002) has prompted much excitement in the
melanoma community. Since this time there has been a
great flurry of papers attempting to determine what this
mutation means, both in terms of clinical significance, as
well as the biochemical behavior of melanoma cells. As yet,
we only have part of the answer, and it seems that BRAF,
although important to this disease, is probably part of a
more complex story. In biochemical terms, the effects of
aberrant RAF activation in cancer are well characterized.
BRAF is a key player in the Ras/Raf/MAP/ERK Kinase
(MEK)/Extracellular Signal Related Kinase (ERK) pathway—
a mitogen-activated protein (MAP) kinase cascade, whose
activation is implicated in a host of cancers through its
myriad effects upon cell growth, invasion, and survival
(reviewed more extensively in Smalley, 2003).
Recent structural biology studies have shown that the
V600E mutation, which accounts for 80% of the reported
mutations (Davies et al, 2002), works by destabilizing the in-
active conformation of BRAF, shifting the equilibrium toward
the active form of the kinase (Wan et al, 2004). Once active,
BRAF activates MEK, which in turn activates ERK. The effects
of increased ERK activity upon melanoma behavior are well
known, and include enhanced cell proliferation, altered inte-
grin expression, decreased E-cadherin expression, increased
matrix metalloproteinase (MMP) secretion, invasion, and the
regulation of the critical melanocyte transcription factor mi-
crophthalmia (Mitf) (reviewed in Smalley, 2003). Proof-of-prin-
ciple in vitro studies demonstrated both that BRAF is an
oncogene in immortalized mouse melanocytes (Wellbrock
et al, 2004) and that selective abrogation of V600E BRAF,
using RNAi, leads to a complete reversal of the melanoma
phenotype—accompanied by reduced MAP kinase activity,
reduced growth, and apoptosis (Hingorani et al, 2003).
From the in vitro data, the BRAF story seems clear, but
life is never that simple, and the in vivo data have been a
little more confusing. In particular, a number of papers have
shown that BRAF mutations are prevalent in unsuspicious
benign nevi (although at levels which range from 21% to
80%) (Pollock et al, 2003). This raises questions about
whether BRAF mutations are acquired at a very early stage
in the oncogenic process, or whether they are actually of
pathological importance at all. The issue is further compli-
cated by the issue of whether nevi truly constitute a pre-
malignant form of melanoma. The data on this subject are
far from clear. Whereas nevi are often precursors for a me-
lanocytic malignancy, many primary melanomas can also
arise de novo, and in many cases the primary melanoma is
never located. It has been further shown that different nevi
from the same patients can harbor different BRAF muta-
tions (Kumar et al, 2004), and that different nevi from the
same patients can harbor either mutant or wild-type BRAF
(Loewe et al, 2004). These findings suggest that the different
BRAF mutations can arise as the result of distinct somatic
events within the same patient (Kumar et al, 2004).
A number of studies have shown that there is some link
between levels of sun-exposure and BRAF mutation status.
In particular, non-sun-exposed sites have a much reduced
incidence of BRAF mutations compared to sites with at
least intermittent sun exposure (see Maldonado et al, 2003).
It was also found that BRAF mutations, however, are rare in
lesions on chronically sun-damaged skin, perhaps hinting
that there are distinct genetic pathways that may lead to
melanoma development (Maldonado et al, 2003).
A new study in this issue of the JID helps to shed more
light on the importance of BRAF in melanoma pathogenesis
(Leowe et al, 2004). In this study, the authors retrospectively
selected 49 lesions, which did not meet the criteria of ma-
lignant melanoma at initial presentation. These lesions were
later excised after a 12-month follow-up—because of either
increased size or structural changes consistent with malig-
nancy. Samples from these lesions were then sequenced for
their BRAF mutation status.
The reasoning behind the current study is simple. First-line
treatment of early melanoma is the complete surgical removal
of the lesion. As benign lesions often display similar structural
alterations and the enhanced proliferation characteristics of
their malignant counterparts, large numbers of benign le-
sions are also removed. As yet, the causes of the rapid
proliferative and structural changes in these lesions are un-
known. One obvious suggestion is that these rapid changes
occur following the acquisition of BRAF mutations. Indeed,
the primary aim of the current study was to determine
whether the BRAF V600E mutation could account for the
1The change of designation from V599E to V600E arose from
complications in sequencing the GC-rich exon 1 of the BRAF gene.
On the July 24, 2003, the sequence was updated, following the
insertion of 3 bp into the coding sequence, resulting in the increase
of the length of the BRAF protein by one amino acid. This therefore
increased the position of all published mutations by one amino
acid and hence V599E became V600E (Richard Wooster, personal
communication). More details can be found at http://www.sanger.
ac.uk/genetics/CGP/cosmic/News/#20040220092805
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observed rapid onset of growth in these melanocytic le-
sions. The results of the study were intriguing. Among
growing lesions, 16 (of which 11 were melanoma and five
nevi) out of 36 had the V600E (referred to as V599E in this
paper) mutation and 4 out of 13 lesions (of which 3 were
melanoma and 1 nevi) that had undergone a structural
change had the V600E mutation. In the control group of 35
lesions that had not undergone proliferative or structural
changes, only 2 had the V600E mutation (both of which
were nevi). When statistically analyzed, these results
showed that the odds of the presence of a BRAF mutation
in rapidly growing lesions were 13 times higher than con-
trols. The odds of finding a BRAF mutation in structurally
altered lesions were 7 times higher than controls. These
data demonstrate that the rapid growth of melanocytic le-
sions correlated with the presence of a V600E BRAF mu-
tation. In this study, there was no correlation seen between
the BRAF mutation status and the site of the original lesion
(whether site of chronic sun exposure, intermittent sun ex-
posure or non-exposure). Although the study showed that
melanomas had a higher incidence of BRAF mutations than
nevi, the levels of mutation were still higher in growing ver-
sus dormant nevi. These findings led the authors to ask two
highly relevant questions: ‘‘Are nevi that harbor the V600E
mutations the precursor lesions of melanoma?’’ and ‘‘Is the
BRAF mutation responsible for the sudden onset of growth
in melanocytic lesions?’’ As yet, these two questions are
rather difficult to answer. The fact that rapidly growing nevi
are more likely to have the V600E mutation, but dormant
nevi do not, suggests there is some link between mutational
status and malignancy. The assertion that the V600E mu-
tation is contributing to enhanced nevus growth is certainly
backed by the available in vitro data (Hingorani et al, 2003;
Wellbrock et al, 2004). The finding, however, that BRAF
V600E is also found in 20%–80% of histologically normal
nevi would dispute this (Pollock et al, 2003). But again, this
may not be the whole story. Primary human cells are no-
toriously hard to transform, and require mutational activa-
tion/inactivation in at least four cellular control circuits.
Typically these can include: growth stimulation through ac-
tivation of the Ras/Raf/MEK/ERK pathway, loss of growth
control via the E2F/pRB pathway, loss of apoptosis through
p53 inactivation/mutation, and telomere maintenance
through activation of telomerase. The mutation and activa-
tion of V600E BRAF alone would be unable to transform a
primary human melanocyte and would instead lead to irre-
versible cell-cycle arrest and senescence. Indeed, it has
been suggested that the melanocytes that make up nevi are
senescent. Adding weight to this argument is the fact that
only melanocytes that were null for the cell cycle inhibitors
p16INK4A and p19ARF were transformed by V600E BRAF
in vitro (Wellbrock et al, 2004). This seems to suggest that
BRAF, like other oncogenes, may also require a genetic
‘‘second hit’’, possibly in the cell-cycle regulation pathway,
in order to be transforming. This then begs the question,
what is the genetic hit that is required for melanoma? The
prime candidate for genetic inactivation in cancer is the p53
pathway, but this is known to be structurally normal in me-
lanoma; however, it is currently unknown whether the p53
pathway is functionally active in this disease.
What is more likely to be important are the other three
known melanoma susceptibility genes, INK4A, CDK4, and
ARF, which are all known to regulate senescence. Indeed,
this idea seems to be born out by a very recent work, in
which genetic analysis of 41 early passage melanoma bi-
opsy cell lines revealed that p16/ARF loss accompanied by
the V600E BRAF mutation was the most prevalent genetic
profile (Daniotti et al, 2004).
The importance of BRAF mutations in melanoma pro-
gression is undoubted; very recent studies have also shown
that there is a definite link between BRAF mutational status
and clinical outcome, with BRAF mutations in melanoma
metastases, but not the primary tumor, being correlated
with poor outcome (Houben et al, 2004). Preliminary results
from clinical trials suggest that RAF-kinase inhibitors, such
as BAY 43-9006, may be of clinical benefit to melanoma
patients, particularly when used in combination with other
drugs. It now seems that the tide is finally turning in the
treatment of melanoma. Understanding more about the role
of BRAF mutations in this disease will play an important role
in guiding our future understanding of the underlying pa-
thology and may lead to much enhanced treatment for this
currently deadly disease.
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